360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Natco Pharma Limited

Type: Company

Name: Natco Pharma Limited (NATCO Pharma Limited)

Fact Sheet: Fact Sheet for Natco Pharma Limited

First reported 13 hours ago - Updated 13 hours ago - 1 reports

Roche Holding AG

Looming Pharma Price War Threatens Indian Oncology Market Growth

The introduction of market-based pricing for all 348 NLEM drugs will prompt pharmaceutical companies to dramatically cut prices in an attempt to maximize profits in a newly devalued sector.The Indian government’s plan to extend market-based pricing to ... [Published PharmaAsia - 13 hours ago]

Entities: Oncology, Therapeutics, Market, Roche Holding AG, CAGR

First reported 19 hours ago - Updated 19 hours ago - 1 reports

Deloitte

European and US investors will turn to India for acquisitions, report says

Even as economic weakness continues to hamper industrial growth in Europe and the US, investors from these countries are set to look to India for mergers and acquisitions, says a new report. The pharmaceutical sector is set to see a good number of acquisitions ... [Published Manufacturing Chemist - 19 hours ago]

Entities: India, Acquisition, Deloitte, Patent

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Sun Pharmaceutical Industries Ltd

India pharmaceuticals market: 18% growth between 2012-2016

India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b in ... [Published TransWorldNews - May 20 2013]

Entities: India, Drugs, Sun Pharmaceutical Industries Ltd, Patent, Inhalation

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Natco recalls breast cancer drug 'Albupax'

Drug firm Natco Pharma today said it has stopped the production and marketing of breast cancer drug 'Albupax', after tests showed that it might cause damage to the liver.The Indian Health Regulator Drug Controller General of India (DCGI) DCGI has sent ... [Published Financial Chronicle - May 20 2013]

Entities: antineoplastic, Breast Cancer, Natco Pharma Limited

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Dr Reddy's Laboratories Ltd

Dr Reddy’s says ‘have factored in the impact’

Pharma major Dr Reddy?s Laboratories Ltd said the new pricing policy might impact 3-4 per cent of its finished dosage sales in the domestic market.The Department of Pharmaceuticals had notified the Drug Prices Control Order 2013, which came into effect ... [Published Hindu Business Line - May 17 2013]

Entities: Satish Reddy, Drugs, Natco Pharma Limited, Dr Reddy's Laboratories Ltd, Dosage

First reported May 09 2013 - Updated May 10 2013 - 2 reports

Indian Patents Act: Incentivising Innovation without compromising affordable healthcare

The recent judgement of the Supreme Court of India in the case of Novartis AG v Union of India[1] has highlighted the protective provisions of Indian Patents Act, 1970, as amended by the Patents (Amendment) Act, 2005, (Patents Act) which imbibe the intent ... [Published Bar & Bench - May 10 2013]

Entities: Patent, India, Drugs

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Health Ministry recommends compulsory licensing of three anti-cancer drugs

The Union Health Ministry has disclosed that it had recommended three cancer drugs, namely, Trastuzumab, Lxabepilone and Dasatinib to the Department of Industrial Policy & Promotion to put them under Compulsory Licensing (CL) under the provisions of the ... [Published PharmaBiz - May 03 2013]

Entities: Ministry of Health, Drugs, Dasatinib

First reported May 01 2013 - Updated May 02 2013 - 3 reports

US 'concerned' over patent norms, innovation climate in India

Washington: Raising questions over innovation climate in India, the US has said the recent decision by India's Supreme Court to prohibit patent of Novartis' cancer drug Glivec could "preclude issuance of a patent" in the country.In its '2013 Special 301 ... [Published zeenews.com - May 02 2013]

Entities: Patent, India, Invention

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Novartis patent row: US ‘concerned’ over India’s patent norms, innovation

In its ?2013 Special 301 Report?, the United States Trade Representative (USTR) also said action by India like allowing of compulsory licensing ?establishes a troubling precedent? and ?raised serious questions about the innovation climate in India?$ $ ... [Published Firstpost.com - May 02 2013]

Entities: Patent, India, Invention, Novartis AG

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Meet tomorrow on removing protection for 3 more anti-cancer formulations

The committee on compulsory licences, set up under the health ministry, is set to meet on Tuesday to reconsider invoking the provision for three key patented anti-cancer medicines - trastuzumab, ixabepilone and dasatinib - sold by multinational pharmaceutical ... [Published Smart Investor - Apr 29 2013]

Entities: Patent, ixabepilone, Dasatinib, Herceptin

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

In the ‘pharmacy of the world’

Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs.Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy?s key architect and member of ... [Published Hindu Business Line - Apr 28 2013]

Entities: Ranbaxy Laboratories Ltd, Drugs, Patent

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

Andhra Pradesh: From bulk drugs to affordable medicines, vaccines

?In Hyderabad, entrepreneurs are driven by a herd mentality. If there is one successful venture, a dozen will follow. The high number of bulk drug manufacturers in a way is just manifestation of such a trend?. Habil Khorakiwala, Chairman of Wockhardt, ... [Published Hindu Business Line - Apr 28 2013]

Entities: Hyderabad (Andhra Pradesh, India), Vaccine, Drugs, Natco Pharma Limited

Quotes

Asked about revenue losses due to recall, the company said, "The sale of product is very insignificant... And the revenues are so small and they don't deserve a mention."

Natco recalls breast cancer drug 'Albupax' [Published Financial Chronicle - May 20 2013]

"We also see companies like GSK and Novartis looking at traditional Chinese medicines (TCM), which may be an if you can't beat 'em, join 'em decision. Anyhow, China's output of TCM is growing rapidly, especially as the government has kept TCM at the centre of its Twelfth Five-Year Plan. Therefore, TCM isn't receding. It looks like Big Pharma is now acknowledging it has to be in that segment too, to have a portfolio that will work in China."

Chinese Pharma Market will Reach $158bn in 2016, Shows New Visiongain Report [Published Individual.com - May 07 2013]

"Unless overturned, the decision could potentially compel innovators outside India ? including those in sectors well beyond pharmaceuticals, such as green technology and information and communications technology ? to manufacture in India in order to avoid being forced to license an invention to third parties."

US 'concerned' over patent norms, innovation climate in India [Published zeenews.com - May 02 2013]

"There is an inherent demand for health care products and services due to India's large patient base and increasing awareness of wellness by its growing population" it said

Patented drug launches could be delayed in India: Deloitte [Published Economic Times - May 01 2013]

More Content

sort by: Date \| Relevance
Looming Pharma Price War Threatens Indian Oncol... [Published PharmaAsia - 13 hours ago]
European and US investors will turn to India fo... [Published Manufacturing Chemist - 19 hours ago]
New Market Report: Natco Pharma Limited (NATCOP... [Published Live-PR.com - May 21 2013]
India pharmaceuticals market: 18% growth betwee... [Published TransWorldNews - May 20 2013]
Natco recalls breast cancer drug 'Albupax' [Published Financial Chronicle - May 20 2013]
Dr Reddy’s says ‘have factored in the impact’ [Published Hindu Business Line - May 17 2013]
Announcing Science in Society 58 [Published Institute of Sciences in Society - May 15 2013]
Indian Patents Act: Incentivising Innovation wi... [Published Bar & Bench - May 10 2013]
Pharmaceutical Patent Ruling Pinches Opportunit... [Published AdvisorOne - May 09 2013]
Chinese Pharma Market will Reach $158bn in 2016... [Published Individual.com - May 07 2013]
Expect a correction in near term, say fund mana... [Published Smart Investor - May 06 2013]
Health Ministry recommends compulsory licensing... [Published PharmaBiz - May 03 2013]
US 'concerned' over patent norms, innovation cl... [Published zeenews.com - May 02 2013]
Novartis patent row: US ‘concerned’ over India’... [Published Firstpost.com - May 02 2013]
Launch of patented drugs could be delayed in In... [Published Firstpost.com - May 02 2013]
Will Indian patent case end drugs companies mon... [Published EHospice - May 02 2013]
Patented drug launches could be delayed in Indi... [Published Economic Times - May 01 2013]
Meet tomorrow on removing protection for 3 more... [Published Smart Investor - Apr 29 2013]
In the ‘pharmacy of the world’ [Published Hindu Business Line - Apr 28 2013]
Andhra Pradesh: From bulk drugs to affordable m... [Published Hindu Business Line - Apr 28 2013]
Don’t overdose on MNC pharma stocks [Published Hindu Business Line - Apr 27 2013]
Little support for pharma MNCs on patent issue [Published Economic Times - Apr 27 2013]
SC verdict on drug patent: will it end monopoly? [Published EHospice - Apr 25 2013]
Pharma in the Crosshairs [Published Corporate Counsel - Apr 19 2013]
Research and Markets: Oncology Therapeutics Mar... [Published Reuters - Apr 18 2013]
Research and Markets: Oncology Therapeutics Mar... [Published Business Wire - Apr 18 2013]
Oncology Therapeutics Market in India to 2018 R... [Published Individual.com - Apr 18 2013]
Natco Pharma Limited (NATCOPHARM) - Financial a... [Published TransWorldNews - Apr 18 2013]
The bitter pill [Published The Week - Apr 16 2013]
SC verdict on Glivec: An IP milestone [Published Express Pharma - Apr 16 2013]

Blogs

sort by: Date \| Relevance
A fool’s game [Published Schumpeter - The Economist - Apr 01 2013] NOVARTIS spent nearly 15 years seeking a patent in India for Glivec, a medicine for chronic myeloid leukemia. That quest reached its dead end, at last, on April 1st. India’s Supreme Court rejected the Swiss drugmaker’s patent application. Glivec ...
India Rejects Bayer Plea Against Cheap Cancer Drug [Published The China Blog - Mar 05 2013] (NEW DELHI) — India‘s patent appeals office has rejected Bayer AG’s plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines ...
India Rejects Bayer Plea Against Cheap Cancer Drug [Published The Middle East Blog - TIME.com - Mar 05 2013] (NEW DELHI) — India‘s patent appeals office has rejected Bayer AG’s plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive lifesaving medicines ...
India Rejects Bayer Appeal On Compulsory License [Published The Big Red Biotech Blog - Mar 04 2013] India's Intellectual Property Appellate board rejected Bayer's appeal fighting a compulsory license to its drug Nexavar. The license was granted last year to the generic manufacturer Natco when authorities determined that Nexavar cost to much for Indian ...
India Rejects Bayer Appeal On Compulsory License [Published Pharmalot - Mar 04 2013] In a blow to multi-national drugmakers, India’s Intellectual Property Appellate board rejected a closely watched appeal from Bayer, which was fighting a compulsory license that permitted the sale of a generic version of its Nexavar cancer drug. The ...

Press Releases

sort by: Date \| Relevance
Research and Markets: Oncology Therapeutics Mar... [Published Business Wire - Apr 18 2013]